Literature DB >> 2184992

Extrathoracic staging of bronchogenic carcinoma.

A Salvatierra1, C Baamonde, J M Llamas, F Cruz, J Lopez-Pujol.   

Abstract

In assessing the value of systematic evaluation of extrathoracic extension for potentially resectable, non-small-cell bronchogenic carcinoma, a prospective study was conducted in 146 patients. The study protocol included computed tomographic (CT) scan of the brain and upper abdomen, abdominal ultrasonography, and whole-body bone scanning. The findings were matched with the clinical presentation, histologic features, and TN staging, having found out that non-small cell bronchogenic carcinoma does not follow a set pattern to metastasize. The rate of metastasis for adenocarcinoma is not only significantly larger (p less than 0.05) but it does not correlate with the TN staging, in contrast to what happens with the squamous cell carcinoma (p less than 0.01). None of the squamous cell carcinomas in intrathoracic stage I was found to metastasize. Twenty-one percent (4/19) of brain metastases were asymptomatic (three adenocarcinomas and one squamous cell carcinoma with multiorgan metastasis). Bone scanning detected metastasis in 3.4 percent (4/116) of the asymptomatic patients, and three of the four patients with asymptomatic metastasis had nonskeletal foci. In 61 percent (11/18) of patients with hepatic metastasis, we did not find organ-specific indicators to suspect it. The series showed a 7.5 percent incidence of adrenal metastasis. Our findings suggest the convenience of performing an upper abdominal CT scan and/or ultrasonography in all patients, except for those with asymptomatic stage I squamous cell carcinoma; we also suggest brain CT scanning for all patients with adenocarcinomas and large-cell carcinomas as well as for those with squamous cell carcinoma with neurologic symptoms, and whole-body bone scanning only in those patients with clinical and laboratory indication of possible bone involvement by metastatic disease.

Entities:  

Mesh:

Year:  1990        PMID: 2184992     DOI: 10.1378/chest.97.5.1052

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy.

Authors:  Marco Spadafora; Leonardo Pace; Luigi Mansi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01       Impact factor: 9.236

Review 2.  Staging for M disease.

Authors:  T L Winton
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

3.  Preoperative screening for metastases in lung cancer.

Authors:  M F Muers
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

4.  Transcutaneous abdominal ultrasonography in the staging of lung cancer.

Authors:  P S Bakke; M Taule; E Lillo; G Melgren; I J Magnussen; O J Halvorsen
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

5.  Surgical treatment of bone metastases in patients with lung cancer.

Authors:  Sandra Utzschneider; Ewa Wicherek; Patrick Weber; Gerwin Schmidt; Volkmar Jansson; Hans Roland Dürr
Journal:  Int Orthop       Date:  2010-06-18       Impact factor: 3.075

6.  Assessment of tumour necrosis and detection of mediastinal lymph node metastasis in bronchial carcinoma with technetium-99m sestamibi imaging: comparison with CT scan.

Authors:  C Aktolun; H Bayhan; Y Pabuccu; H Bilgic; H Acar; R Koylu
Journal:  Eur J Nucl Med       Date:  1994-09

Review 7.  Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer.

Authors:  T K Hillers; M D Sauve; G H Guyatt
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

8.  Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer.

Authors:  Holger Schirrmeister; Coskun Arslandemir; Gerhard Glatting; Regine Mayer-Steinacker; Martin Bommer; Karsten Dreinhöfer; Andreas Buck; Martin Hetzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-28       Impact factor: 9.236

9.  Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms.

Authors:  Takahiro Ando; Hidenori Kage; Minako Saito; Yosuke Amano; Yasushi Goto; Jun Nakajima; Takahide Nagase
Journal:  Int J Clin Oncol       Date:  2018-02-26       Impact factor: 3.402

10.  Can clinical factors be determinants of bone metastases in non-small cell lung cancer?

Authors:  Ahmet Ursavas; Mehmet Karadag; Esra Uzaslan; Erkan Rodoplu; Ezgi Demirdögen; Basak Burgazlioglu; R Oktay Gozu
Journal:  Ann Thorac Med       Date:  2007-01       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.